HUP0401855A2 - Pirimidin-származékok mint az inzulinszerű növekedési faktor-1 receptor (IGF-1R) modulátorai, eljárás előállításukra, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények - Google Patents
Pirimidin-származékok mint az inzulinszerű növekedési faktor-1 receptor (IGF-1R) modulátorai, eljárás előállításukra, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0401855A2 HUP0401855A2 HU0401855A HUP0401855A HUP0401855A2 HU P0401855 A2 HUP0401855 A2 HU P0401855A2 HU 0401855 A HU0401855 A HU 0401855A HU P0401855 A HUP0401855 A HU P0401855A HU P0401855 A2 HUP0401855 A2 HU P0401855A2
- Authority
- HU
- Hungary
- Prior art keywords
- alkyl
- group
- carbonyl
- hydroxyl
- substituent
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- -1 amino, hydroxyl Chemical group 0.000 abstract 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 6
- 229910052799 carbon Inorganic materials 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
A találmány az (I) általános képletű vegyületekre, továbbá azokgyógyászatilag alkalmazható sóira és szolvátjaira vonatkozik - aképletben R1 legalább 1 nitrogén-, oxigén- és/vagy kén-heteroatomottartalmazó öt vagy hattagú heteroaromás gyűrűt jelent, amihez adottesetben legalább 1 szubsztituens, éspedig halogénatom, adott esetbenlegalább 1 halogén-, amino-, hidroxil vagy trifluor-metil-szubsztituenst hordozó 1-6 szénatomos alkil- vagy 1-6 szénatomosalkoxicsoport, nitro-, ciano-, karboxil-, hidroxil-, 2-6 szénatomosalkenil-, 3-6 szénatomos cikloalkil-, (1-6 szénatomos alkoxi)-karbonil-, (1-6 szénatomos alkil)-karbonil-, (1-6 szénatomos alkil)-karbonil-amino- vagy fenil-karbonil-csoport, -NR5R6, -S(O)m-(1-6szénatomos alkil)-, -C(O)NR7R8 vagy -SO2NR7aR8a általános képletűcsoport vagy adott esetben legalább 1 nitrogén-, oxigén- és/vagy kén-heteroatomot tartalmazó, öt- vagy hattagú telítetlen gyűrűkapcsolódhat, és az utóbbi telítetten gyűrű adott esetben legalább 1szubsztituenst, éspedig halogénatomot, adott esetben legalább 1halogén-, amino-, hidroxil- vagy trifluor-metil-szubsztituenst hordozó1-6 szénatomos alkil- vagy 1-6 szénatomos alkoxicsoportot, nitro-,ciano-, karboxil-, hidroxil-, 2-6 szénatomos alkenil-, 3-6 szénatomoscikloalkil-, (1-6 szénatomos alkoxi)-karbonil-, (1-6 szénatomosalkil)-karbonil-, (1-6 szénatomos alkil)-karbonil-amino- vagy fenil-karbonil-csoportot vagy -NR9R10, -S(O)n-(1-6 szénatomos alkil)-, -C(O)NR11R12 vagy -SO2NR11aR12a általános képletű csoportot hordozhat;R2 1-4 szénatomos alkilcsoportot jelent, amihez adott esetben legalább1 halogén-, hidroxil- vagy 1-3 szénatomos alkoxi-szubsztituenskapcsolódhat; R3 hidrogénatomot, halogénatomot vgy trifluor-metil-csoportot jelent; és R4 legalább 1 nitrogén-, oxigén- és/vagy kén-heteroatomot tartalmazó öttagú heteroaromás gyűrűt jelent, amihezadott esetben legalább 1 szubsztituens, éspedig halogénatom, adottesetben legalább 1 halogén-, amino-, hidroxil- vagy trifluor-metil-szubsztituenst hordozó 1-6 szénatomos alkil- vagy 1-6 szénatomosalkoxicsoport, nitro-, ciano-, karboxil-, hidroxil-, 2-6 szénatomosalkenil-, 3-6 szénatomos cikloalkil-, (1-4 szénatomos alkoxi)-karbonil-, (1-4 szénatomos alkil)-karbonil-, (1-4 szénatomos alkil)-karbonil-amino- vagy fenil-karbonil-csoport, vagy -NR13R14, -S(O)p(1-4szénatomos alkil)-, -C(O)NR15R16 vagy -SO2NR15aR16a általános képletűcsoport kapcsolódhat. A fenti vegyületek előállítása és a fentivegyületeket tartalmazó gyógyászati készítmények is a találmánytárgyát képezik. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0104140A SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Novel Compounds |
PCT/SE2002/002221 WO2003048133A1 (en) | 2001-12-07 | 2002-12-03 | Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-i) |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0401855A2 true HUP0401855A2 (hu) | 2004-12-28 |
HUP0401855A3 HUP0401855A3 (en) | 2008-06-30 |
Family
ID=20286257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0401855A HUP0401855A3 (en) | 2001-12-07 | 2002-12-03 | Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-ir), process for their preparation, their use and pharmaceutical compositions containing them |
Country Status (33)
Country | Link |
---|---|
US (3) | US7521453B2 (hu) |
EP (1) | EP1456182B1 (hu) |
JP (1) | JP4347051B2 (hu) |
KR (1) | KR100930558B1 (hu) |
CN (1) | CN1289486C (hu) |
AR (1) | AR037736A1 (hu) |
AT (1) | ATE425150T1 (hu) |
AU (1) | AU2002365864B2 (hu) |
BR (1) | BR0214605A (hu) |
CA (1) | CA2467838C (hu) |
CO (1) | CO5590919A2 (hu) |
CY (1) | CY1109101T1 (hu) |
DE (1) | DE60231542D1 (hu) |
DK (1) | DK1456182T3 (hu) |
EG (1) | EG24930A (hu) |
ES (1) | ES2323125T3 (hu) |
HK (1) | HK1067631A1 (hu) |
HU (1) | HUP0401855A3 (hu) |
IL (2) | IL162376A0 (hu) |
IS (1) | IS7294A (hu) |
MX (1) | MXPA04005347A (hu) |
MY (1) | MY135705A (hu) |
NO (1) | NO327502B1 (hu) |
NZ (1) | NZ533130A (hu) |
PL (1) | PL369528A1 (hu) |
PT (1) | PT1456182E (hu) |
RU (1) | RU2317291C2 (hu) |
SE (1) | SE0104140D0 (hu) |
SI (1) | SI1456182T1 (hu) |
TW (1) | TWI324152B (hu) |
UA (1) | UA78259C2 (hu) |
WO (1) | WO2003048133A1 (hu) |
ZA (1) | ZA200404223B (hu) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
US7517886B2 (en) | 2002-07-29 | 2009-04-14 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
CN102358738A (zh) | 2003-07-30 | 2012-02-22 | 里格尔药品股份有限公司 | 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途 |
DE602004032446D1 (de) * | 2003-08-07 | 2011-06-09 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel |
JP4916883B2 (ja) | 2003-10-15 | 2012-04-18 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | イミダゾピラジンチロシンキナーゼ阻害剤 |
CA2542522A1 (en) | 2003-10-17 | 2005-05-06 | Astrazeneca Ab | 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer |
MY141220A (en) * | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
CN100590118C (zh) | 2004-03-12 | 2010-02-17 | 阿纳里特康股份有限公司 | 作为类胰岛素生长因子第1类受体抑制剂的杂环化合物 |
WO2005097765A1 (en) * | 2004-03-31 | 2005-10-20 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
WO2005097800A1 (en) * | 2004-04-02 | 2005-10-20 | Osi Pharmaceuticals, Inc. | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
DE102004022897A1 (de) * | 2004-05-10 | 2005-12-08 | Bayer Cropscience Ag | Azinyl-imidazoazine |
AR053090A1 (es) | 2004-07-20 | 2007-04-25 | Osi Pharm Inc | Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos |
CA2584295C (en) | 2004-11-24 | 2014-08-26 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
EP1841760B1 (en) * | 2004-12-30 | 2011-08-10 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
DE602006010979D1 (de) | 2005-01-19 | 2010-01-21 | Rigel Pharmaceuticals Inc | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
RS52061B (en) | 2005-02-04 | 2012-04-30 | Astrazeneca Ab | PIRAZOLYL-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS |
WO2006087530A1 (en) | 2005-02-16 | 2006-08-24 | Astrazeneca Ab | Chemical compounds |
GB0507347D0 (en) * | 2005-04-12 | 2005-05-18 | Astrazeneca Ab | Chemical compounds |
WO2006115452A1 (en) * | 2005-04-27 | 2006-11-02 | Astrazeneca Ab | Use of pyrazolyl-pyrimidine derivatives in the treatment of pain |
EP1899323A2 (en) * | 2005-05-16 | 2008-03-19 | AstraZeneca AB | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US7566721B2 (en) * | 2005-08-08 | 2009-07-28 | Osi Pharmaceuticals, Inc. | Substituted thienol[2,3-d]pyrimidines as kinase inhibitors |
AR056471A1 (es) | 2005-08-24 | 2007-10-10 | Wyeth Corp | Formulaciones de acetato de bazedoxifeno |
WO2007035744A1 (en) | 2005-09-20 | 2007-03-29 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
BRPI0618011A2 (pt) * | 2005-10-28 | 2011-08-16 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente |
AR057960A1 (es) * | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
BRPI0712052A2 (pt) * | 2006-06-09 | 2012-01-10 | Novartis Ag | polipeptìdeos de fator de crescimento tipo insulina estabilizados |
MX2008016007A (es) * | 2006-06-15 | 2009-01-16 | Boehringer Ingelheim Int | 2-anilino-4-aminoalquilenoaminopirimidinas. |
AU2007263655A1 (en) * | 2006-06-30 | 2008-01-03 | Astrazeneca Ab | Pyrimidine derivatives useful in the treatment of cancer |
US8222256B2 (en) | 2006-07-05 | 2012-07-17 | Exelixis, Inc. | Methods of using IGFIR and ABL kinase modulators |
EP2155742A1 (en) * | 2007-04-18 | 2010-02-24 | AstraZeneca AB | 5-aminopyrazol-3-yl-3h-imidazo [4,5-b]pyridine derivatives and their use for the treatment of cancer |
ATE521609T1 (de) * | 2007-05-04 | 2011-09-15 | Astrazeneca Ab | Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs |
UA99459C2 (en) * | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
US8178091B2 (en) | 2007-05-21 | 2012-05-15 | University Of Washington | Compositions and methods for the treatment of respiratory disorders |
WO2009019518A1 (en) * | 2007-08-09 | 2009-02-12 | Astrazeneca Ab | Pyrimidine compounds having a fgfr inhibitory effect |
WO2009091939A1 (en) * | 2008-01-18 | 2009-07-23 | Osi Pharmaceuticals, Inc. | Imidazopyrazinol derivatives for the treatment of cancers |
JP2011520970A (ja) * | 2008-05-19 | 2011-07-21 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 置換されたイミダゾピラジン類およびイミダゾトリアジン類 |
JP2011522870A (ja) * | 2008-06-11 | 2011-08-04 | アストラゼネカ アクチボラグ | 癌および骨髄増殖性障害の処置に有用な三環式2,4−ジアミノ−l,3,5−トリアジン誘導体 |
DE102008041214A1 (de) | 2008-08-13 | 2010-02-18 | Bayer Cropscience Ag | N-substituierte Azinylakyl-azincarboxamide und deren Analoge |
CA2737217A1 (en) * | 2008-09-30 | 2010-04-08 | Astrazeneca Ab | Heterocyclic jak kinase inhibitors |
US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
WO2010099137A2 (en) | 2009-02-26 | 2010-09-02 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the emt status of tumor cells in vivo |
JP2012519282A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010123792A1 (en) | 2009-04-20 | 2010-10-28 | Osi Pharmaceuticals, Inc. | Preparation of c-pyrazine-methylamines |
EP2427192A1 (en) * | 2009-05-07 | 2012-03-14 | OSI Pharmaceuticals, LLC | Use of osi-906 for treating adrenocortical carcinoma |
US20100316639A1 (en) | 2009-06-16 | 2010-12-16 | Genentech, Inc. | Biomarkers for igf-1r inhibitor therapy |
US20110217309A1 (en) | 2010-03-03 | 2011-09-08 | Buck Elizabeth A | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
JP2013527748A (ja) | 2010-03-03 | 2013-07-04 | オーエスアイ・ファーマシューティカルズ,エルエルシー | インスリン様増殖因子1受容体キナーゼ阻害剤に対する抗癌反応の予測に役立つ生物学的マーカー |
JP2013522215A (ja) | 2010-03-09 | 2013-06-13 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 組合わせ抗癌療法 |
CN102970867A (zh) | 2010-03-18 | 2013-03-13 | 拜耳知识产权有限责任公司 | 作为活性剂对抗非生物植物应激的芳基和杂芳基磺酰胺 |
AU2011254550B2 (en) | 2010-05-21 | 2013-11-07 | Noviga Research Ab | Novel pyrimidine derivatives |
UY33817A (es) * | 2010-12-21 | 2012-07-31 | Boehringer Ingelheim Int | ?nuevas oxindolpirimidinas bencílicas?. |
JP2014510265A (ja) | 2011-02-02 | 2014-04-24 | アムジェン インコーポレイテッド | Igf−1rの阻害に関する方法および組成物 |
US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
CA2830129C (en) | 2011-03-24 | 2016-07-19 | Chemilia Ab | Novel pyrimidine derivatives |
US9096691B2 (en) | 2011-04-13 | 2015-08-04 | Eastman Chemical Company | Cellulose ester optical films |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
EP2776042B1 (en) | 2011-11-11 | 2019-03-20 | Duke University | Combination drug therapy for the treatment of solid tumors |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
US8980259B2 (en) | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
WO2014134202A1 (en) | 2013-02-26 | 2014-09-04 | Triact Therapeutics, Inc. | Cancer therapy |
US9381246B2 (en) | 2013-09-09 | 2016-07-05 | Triact Therapeutics, Inc. | Cancer therapy |
WO2017129763A1 (en) | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer |
CN115124475B (zh) * | 2022-07-11 | 2023-11-10 | 贵阳学院 | 一种嘧啶衍生物及其制备方法和用途 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1417402A (en) * | 1972-03-30 | 1975-12-10 | Boots Co Ltd | Pharmacologically active anilinobenzothiazoles |
DE2426180A1 (de) * | 1974-05-29 | 1975-12-18 | Bayer Ag | Verfahren zum faerben von polyurethankunststoffen |
US4485284A (en) * | 1982-01-11 | 1984-11-27 | Advanced Moisture Technology, Inc. | Apparatus and process for microwave moisture analysis |
HU206337B (en) * | 1988-12-29 | 1992-10-28 | Mitsui Petrochemical Ind | Process for producing pyrimidine derivatives and pharmaceutical compositions |
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
CA2104053C (en) * | 1992-08-31 | 1999-04-13 | Miguel A. Cacho | Automated fluid bed process |
US5935966A (en) | 1995-09-01 | 1999-08-10 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
JPH11512390A (ja) | 1995-09-01 | 1999-10-26 | シグナル ファーマシューティカルズ,インコーポレイテッド | ピリミジンカルボキシレートおよび関連化合物ならびに炎症状態を処置するための方法 |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
DK0970369T3 (da) * | 1997-03-27 | 2002-01-28 | Glatt Gmbh | Fremgangsmåde til overvågning og/eller styring og regulering af en granulerings-, agglomererings-, instantiserings-, coating- og tørringsproces i en fluid bed eller bevæget ..... |
US6247246B1 (en) * | 1998-05-27 | 2001-06-19 | Denver Instrument Company | Microwave moisture analyzer: apparatus and method |
DE69933680T2 (de) | 1998-08-29 | 2007-08-23 | Astrazeneca Ab | Pyrimidine verbindungen |
OA11674A (en) | 1998-11-10 | 2005-01-12 | Janssen Pharmaceutica Nv | HIV Replication inhibiting pyrimidines. |
US6337338B1 (en) | 1998-12-15 | 2002-01-08 | Telik, Inc. | Heteroaryl-aryl ureas as IGF-1 receptor antagonists |
GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
DE19917785A1 (de) * | 1999-04-20 | 2000-10-26 | Bayer Ag | 2,4-Diamino-pyrimidin-Derivate |
GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
US6399780B1 (en) * | 1999-08-20 | 2002-06-04 | Cephalon, Inc. | Isomeric fused pyrrolocarbazoles and isoindolones |
EA005423B1 (ru) * | 1999-09-24 | 2005-02-24 | Янссен Фармацевтика Н.В. | Противовирусные композиции |
US6455525B1 (en) * | 1999-11-04 | 2002-09-24 | Cephalon, Inc. | Heterocyclic substituted pyrazolones |
WO2001060816A1 (en) | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004887D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
DK1282607T3 (en) * | 2000-05-08 | 2016-02-01 | Janssen Pharmaceutica Nv | Prodrugs of HIV replication inhibiting pyrimidines |
US6613776B2 (en) * | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6610677B2 (en) * | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
AU2001292670A1 (en) * | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
BR0116411A (pt) * | 2000-12-21 | 2003-11-11 | Vertex Pharma | Compostos de pirazol úteis como inibidores de proteìna cinase |
JP4342939B2 (ja) * | 2001-08-03 | 2009-10-14 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピラゾール誘導キナーゼインヒビターおよびその使用 |
US6750239B2 (en) * | 2001-08-03 | 2004-06-15 | Vertex Pharmaceuticals Incorporated | Pyrazole-derived kinase inhibitors and uses thereof |
US6747461B2 (en) * | 2001-10-25 | 2004-06-08 | Pioneer Hi-Bred International, Inc. | Apparatus and method for monitoring drying of an agricultural porous medium such as grain or seed |
SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
MY141220A (en) * | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
US7528138B2 (en) * | 2004-11-04 | 2009-05-05 | Vertex Pharmaceuticals Incorporated | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
WO2006087530A1 (en) * | 2005-02-16 | 2006-08-24 | Astrazeneca Ab | Chemical compounds |
CN101316843B (zh) * | 2005-11-03 | 2013-01-02 | 顶点医药品公司 | 用作激酶抑制剂的氨基嘧啶 |
AU2007263655A1 (en) * | 2006-06-30 | 2008-01-03 | Astrazeneca Ab | Pyrimidine derivatives useful in the treatment of cancer |
TW200823196A (en) * | 2006-11-01 | 2008-06-01 | Astrazeneca Ab | New use |
TW200826937A (en) * | 2006-11-01 | 2008-07-01 | Astrazeneca Ab | New use |
-
2001
- 2001-12-07 SE SE0104140A patent/SE0104140D0/xx unknown
-
2002
- 2002-03-12 UA UA20040705367A patent/UA78259C2/uk unknown
- 2002-12-02 TW TW091134937A patent/TWI324152B/zh not_active IP Right Cessation
- 2002-12-03 IL IL16237602A patent/IL162376A0/xx unknown
- 2002-12-03 ES ES02791165T patent/ES2323125T3/es not_active Expired - Lifetime
- 2002-12-03 DE DE60231542T patent/DE60231542D1/de not_active Expired - Lifetime
- 2002-12-03 CA CA2467838A patent/CA2467838C/en not_active Expired - Fee Related
- 2002-12-03 PT PT02791165T patent/PT1456182E/pt unknown
- 2002-12-03 PL PL02369528A patent/PL369528A1/xx not_active Application Discontinuation
- 2002-12-03 MX MXPA04005347A patent/MXPA04005347A/es active IP Right Grant
- 2002-12-03 US US10/497,744 patent/US7521453B2/en not_active Expired - Fee Related
- 2002-12-03 EP EP02791165A patent/EP1456182B1/en not_active Expired - Lifetime
- 2002-12-03 NZ NZ533130A patent/NZ533130A/en not_active IP Right Cessation
- 2002-12-03 WO PCT/SE2002/002221 patent/WO2003048133A1/en active Application Filing
- 2002-12-03 SI SI200230824T patent/SI1456182T1/sl unknown
- 2002-12-03 AU AU2002365864A patent/AU2002365864B2/en not_active Ceased
- 2002-12-03 BR BR0214605-3A patent/BR0214605A/pt not_active IP Right Cessation
- 2002-12-03 DK DK02791165T patent/DK1456182T3/da active
- 2002-12-03 JP JP2003549325A patent/JP4347051B2/ja not_active Expired - Fee Related
- 2002-12-03 KR KR1020047008612A patent/KR100930558B1/ko not_active IP Right Cessation
- 2002-12-03 HU HU0401855A patent/HUP0401855A3/hu unknown
- 2002-12-03 CN CNB02827802XA patent/CN1289486C/zh not_active Expired - Fee Related
- 2002-12-03 AT AT02791165T patent/ATE425150T1/de active
- 2002-12-03 RU RU2004121029/04A patent/RU2317291C2/ru not_active IP Right Cessation
- 2002-12-04 MY MYPI20024549A patent/MY135705A/en unknown
- 2002-12-06 AR ARP020104747A patent/AR037736A1/es unknown
-
2004
- 2004-05-28 ZA ZA200404223A patent/ZA200404223B/en unknown
- 2004-06-03 IS IS7294A patent/IS7294A/is unknown
- 2004-06-03 CO CO04052141A patent/CO5590919A2/es not_active Application Discontinuation
- 2004-06-06 IL IL162376A patent/IL162376A/en not_active IP Right Cessation
- 2004-06-06 EG EGNA2004000039 patent/EG24930A/xx active
- 2004-07-06 NO NO20042872A patent/NO327502B1/no not_active IP Right Cessation
-
2005
- 2005-01-06 HK HK05100089.7A patent/HK1067631A1/xx not_active IP Right Cessation
-
2009
- 2009-01-26 US US12/359,541 patent/US20090131463A1/en not_active Abandoned
- 2009-05-25 CY CY20091100558T patent/CY1109101T1/el unknown
-
2011
- 2011-12-07 US US13/313,097 patent/US20120095011A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0401855A2 (hu) | Pirimidin-származékok mint az inzulinszerű növekedési faktor-1 receptor (IGF-1R) modulátorai, eljárás előállításukra, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények | |
BR1100514A (pt) | Processo para a preparação de compostos derivados do ácido benzimidazolino - 2 - oxo - 1 - carboxìlico; produto / composto / composição | |
NO304070B1 (no) | Benzimidazolon-derivater, farmasöytiske preparater inneholdende dem og anvendelse av dem | |
HUP0302922A2 (hu) | Sejtburjánzást gátló hatású imidazolo-5-il-2-anilino-pirimidinek és ezeket tartalmazó gyógyszerkészítmények | |
HUP0201646A2 (hu) | Új alfa-aminosav vegyületek, eljárás ezek előállítására, és ezeket tartalmazó gyógyászati készítmények | |
NO883587D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive indolderivater. | |
MX19368A (es) | Procedimiento para la preparacion de derivados heterociclicos que contienen nitrogeno benzofusionado y compuesto obtenido. | |
DK0790987T3 (da) | Aminotetrazol-derivater, der er anvendelige som nitrogenoxidsynthaseinhibitorer | |
ATE307145T1 (de) | Verwendung von phenylhydrazonderivaten als antiinflammatorische und analgetische mittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |